Meeting
2023 ASCO Annual Meeting
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.
Authors
Shwetal Mehta
Ivy Brain Tumor Center, Phoenix, AZ
Shwetal Mehta , Nader Sanai , Tigran Margaryan , Jennifer Molloy , Hualin Zhang , William Knight , Jocelyn Harmon , Amy Hong , John Wanebo , Kelly Braun , William R. Kennedy , Michael A. Garcia , Igor J. Barani , Wonsuk Yoo , An-Chi Tien , Artak Tovmasyan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT05076513
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2069)
DOI
10.1200/JCO.2023.41.16_suppl.2069
Abstract #
2069
Poster Bd #
426
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2022 ASCO Annual Meeting
Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
First Author: Patrick Y. Wen
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon